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The TLR2/6 ligand PAM2CSK4 is a Th2
polarizing adjuvant in Leishmania major
and Brugia malayi murine vaccine models
Alice Halliday1, Joseph D. Turner1, Ana Guimarães1, Paul A. Bates2 and Mark J. Taylor1*
Abstract
Background: Toll-like receptors (TLRs) play an important role in the innate and adaptive immune responses to
pathogens, and are the target of new vaccine adjuvants. TLR2 plays a role in parasite recognition and activation of
immune responses during cutaneous leishmaniasis infection, suggesting that TLR2 could be targeted by adjuvants
for use in Leishmania vaccines. We therefore explored using Pam2CSK4 (Pam2) and Pam3CSK4 (Pam3) lipopeptide
adjuvants, which activate TLR2/6 and TLR2/1 heterodimers respectively, in vaccine models for parasitic infections.
Methods: The use of lipopeptide adjuvants was explored using two vaccine models. For cutaneous leishmaniasis,
the lipopeptide adjuvants Pam2 and Pam3 were compared to that of the Th1-driving double-stranded DNA TLR9
agonist CpG for their ability to improve the efficacy of the autoclaved Leishmania major (ALM) vaccine to protect
against L. major infection. The ability of Pam2 to enhance the efficacy of a soluble Brugia malayi microfilariae extract
(BmMfE) vaccine to protect against filarial infection was also assessed in a peritoneal infection model of B. malayi
filariasis. Parasite antigen-specific cellular and humoral immune responses were assessed post-challenge.
Results: The use of lipopeptides in ALM-containing vaccines did not provide any protection upon infection with L.
major, and Pam2 exacerbated the disease severity in vaccinated mice post-challenge. Pam2, and to a lesser extent
Pam3, were able to elevate antigen-specific immune responses post-challenge in this model, but these responses
displayed a skewed Th2 phenotype as characterised by elevated levels of IgG1. In the B. malayi vaccine model,
the use of Pam2 as an adjuvant with BmMfE induced significant protective immunity to the same level as
inclusion of an Alum adjuvant. Here, both Pam2 and Alum were found to enhance antigen-specific antibody
production post-challenge, and Pam2 significantly elevated levels of antigen-specific IL-4, IL-5 and IL-13 produced
by splenocytes.
Conclusions: These data indicate that TLR2/6-targeting ligands could be considered as adjuvants for vaccines
that require robust Th2 and/or antibody-dependent immunity.
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Background
Toll-like receptor (TLR)s are innate immune receptors
which recognise distinct molecular patterns (pathogen-
associated molecular patterns; PAMPs) of microbial or-
ganisms. Due to their ability to promote strong innate
and adaptive immune responses, TLR ligands are a
promising new class of adjuvants [1]. Many TLR ligand
formulations have been included in experimental vac-
cines in human clinical trials, implicating them as safe
and efficacious adjuvants, but so far only two, which
both contain the TLR4 ligand 3-O-desacyl-4’-monopho-
sphoryl lipid A (MPL), have been licensed for use in
human vaccines: the Adjuvant System 04 (ASO4;
GlaxoSmithKline) is an oil-in water adjuvant and is li-
censed for use in the human papilloma virus (HPV) vac-
cine, and RC-529 which contains Alum and is licenced
for use in the hepatitis B vaccine [1–3]. Clearance of
parasitic infections requires different types of adaptive
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immune response depending on the type of causative
pathogen, with intracellular protozoa (such as Plasmo-
dium and Leishmania spp) requiring a Th1-type immune
response, while extracellular parasitic helminths (such as
filarial nematodes) require a Th2 response. Thus, the use
of parasitic models of infection in preclinical vaccine
studies can allow us to explore the ability of different
vaccine and adjuvant formulations to drive immune re-
sponses post challenge. Some TLR ligands, such as vari-
ous TLR4 ligands and the TLR9 ligand CpG, have shown
good efficacy in preclinical vaccine studies of malaria
and leishmaniasis [4–8].
TLR2 has been implicated in the recognition of
Leishmania parasites [9, 10], and in playing a role
during infection in vivo [11]. A widely used vaccine
model for cutaneous leishmaniasis is heat-killed auto-
claved L. major (ALM) given in two doses (prime and
boost) prior to challenge with L. major promastigotes
[7, 12–14]. In mice, the ALM vaccine provides good
efficacy to challenge infections with Leishmania para-
sites [7, 15]. CpG, an agonist of TLR9, elicits a strong
Th1 response to a killed whole-cell L. major vaccine
in susceptible BALB/c mice, and provides protection
in 40 % of animals receiving the vaccine [12]. Whilst
the ability of whole-cell Leishmania vaccines to pro-
vide long term protective immunity has been dis-
puted, Okwor et al. [15] demonstrated that repeated
inoculation with ALM could result in the expansion
of sufficient Th1 memory T cells specific for L. major and
this strategy was as effective as live parasites at providing
protection to challenge up to 13 weeks after the final dose
was given. This demonstrates that the use of first gener-
ation killed parasite vaccines can provide protection to L.
major when delivered in the appropriate manner, and
stimulates the search for the most appropriate adjuvants
to increase the efficacy of these vaccines.
TLR2 and its co-receptor TLR6 have also been found
to play a role in disease pathogenesis during infection
with the filarial parasite, Brugia malayi, which causes
lymphatic filariasis. In this setting, TLR2 is activated by
a lipopeptide from the bacterial endosymbiont of B.
malayi, Wolbachia [16, 17]. Mouse models to assess the
efficacy of experimental vaccines to protect against
lymphatic filariasis have used various forms of antigen,
including recombinant proteins, DNA vaccines, and at-
tenuated larvae, of which the latter has had the greatest
success [18, 19]. Given that using attenuated parasite lar-
vae is not feasible for a licensed vaccine, finding an
alternative approach using protein and adjuvant combi-
nations would be advantageous. As with resistance to
primary infections, both T and B cell responses appear
to be crucial for enhanced clearance to filarial infections
in vaccinated mice, as well as the production of IL-5 and
subsequent recruitment of eosinophils [20–22].
Lipopeptides are agonists for TLR2 and their ability to
stimulate both cellular and humoural immune responses
has been widely reported [23–25], but their use as adju-
vants in vaccines for parasitic infections remains rela-
tively unexplored. In this study, we aimed to explore the
use of lipopeptides as potential new adjuvants for use in
vaccine models against two different parasitic infections:
Leishmania major which requires Th1 immunity, and
Brugia malayi, which requires Th2 immunity [26].
Methods
Mice and parasites
All procedures involving the use of laboratory animals
were performed at the Biomedical Services Unit (BSU),
University of Liverpool, were approved by the Ethics and
Animal Care Committees of the University of Liverpool
and Liverpool School of Tropical Medicine (LSTM), and
were carried out according to the Animals (Scientific
Procedures) Act (UK Home Office).
Female C57BL/6 mice were purchased from Charles
River (UK) for use in Leishmania infection/ vaccine ex-
periments, while male BALB/c mice were purchased
from Harlan (UK) for B. malayi infection/ vaccine ex-
periments; all were 8–10 weeks at the start of each ex-
periment. Animals were randomly allocated in to groups
for vaccination and challenge experiments. While down-
stream analysis on the outcomes of animal experiments
was not performed blind to experimental groups, indi-
vidual samples from different groups were mixed during
measurement and analysis, to ensure no bias was
introduced.
L. major FV1 (MHOM/IL/80/Friedlin) promastigote
parasites were cultured in complete M199 medium
(Invitrogen, containing 10–20 % heat-inactivated foetal
calf serum (PAA), BME vitamins (Sigma), and 25 μg/ml
gentamicin sulphate (Sigma)) and were sub-passaged no
more than twice after initial culture of lesion-derived
amastigotes. For the infectious challenge, parasites were
enriched for metacyclics as described elsewhere [27].
The B. malayi life cycle was maintained at LSTM as
described [18]. Jirds infected in the peritoneum with
adult B. malayi parasites were originally purchased from
TRS laboratories, USA. Microfilariae (Mf) produced by
B. malayi adults were obtained by a peritoneal tapping
method, as described by Griffiths [28].
Leishmania whole cell vaccines, vaccination and challenge
infection
Autoclaved L. major (ALM) antigen was made using a
method described first by Bahar et al. [29]. Briefly, L.
major promastigote cultures were grown to log-phase
(day 5) in complete M199 and diluted 1:5 in complete
Grace’s medium for a further 4 days. The promastigote
parasites (approximately 109) were then washed (X3) in
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sterile phosphate buffered saline (PBS) and resuspended
in 2 ml in a glass container and autoclaved at 151 °C for
15 minutes. Protein concentration was measured using
the BCA assay (Pierce/ThermoScientific) and aliquots
were stored at –80 °C. The unmethylated CpG Oligo-
deoxynucleotide (ODN) 1826 adjuvant of the sequence
5’- TCCATGACGTTCCTGACGTT -3’ (CpG) was a
kind gift from Lyn Jones and Matthew Selby at Coley
(Pfizer). Lipopeptide adjuvants S-[2,3-bis(palmitoyloxy)-
(2RS)-propyl]-(R)-cysteine (Pam2) and N-Palmitoyl-S-
[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine (Pam3)
were purchased from EMC Microcollections. CpG,
Pam2 and Pam3 were dissolved in nuclease-free water
and stored as 1–10 mg/ml stocks at –80 °C.
Mice were immunised with 20 μl of PBS alone; 50 μg
ALM; 50 μg ALM + 50 μg CpG; 50 μg ALM + 10 μg
Pam2; 50 μg ALM + 10 μg Pam3. The first dose was
given s.c to the upper side of the left hind foot (LHF),
and the second dose was given s.c to the shaven rump
two weeks later. Four weeks after the second vaccine
dose, mice were challenged by s.c. injection of 105
metacyclic-enriched L. major FV1 parasites, in 20 μl
Hank’s Balanced Salt solution (HBSS, Sigma), to the
upper side of the right hind foot (RHF).
Measurement of lesion size on the infected foot was
achieved by measuring the thickness of the two hind feet
using a dial calliper and subtracting the thickness of the
uninfected foot from that of the infected foot (mm).
B. malayi vaccines, vaccinations and challenge infection
B. malayi Mf parasite extract (BmMfE) was prepared as
previously described [30] with some adjustments. Mf
were separated from the peritoneal exudate using a PD-
10 column (GE Life Sciences) and resuspended in sterile
PBS at 2 × 106/ml prior to sonication and centrifugation
[30]. Imject® Alum Adjuvant (Alum, Thermo Scientific)
was added dropwise to BmMfE to a ratio of 1:1 and
mixed for 30 min at 4 °C. Mice were immunised with
100 μl s.c at the nape of the neck with either: PBS; 50 μg
BmMfE; 50 μg BmMfE + 10 μg Pam2; 50 μg BmMfE +
Alum. Two weeks later, mice were challenged with 50 B.
malayi L3 by i.p injection. Parasites were recovered six
or nine days post challenge.
Immune responses
The levels of antigen specific IgG1, IgG2c (C57BL/6
mice) and IgG2a (BALB/c mice) in plasma samples from
mice were measured using a sandwich antibody ELISA
(Bethyl Laboratories) with L. major freeze thaw antigen
(FTAg; Leishmania experiments) or BmMfE; (B. malayi
experiments) as the capture antigen at a concentration
of 10 μg/ml.
To assess recall responses, splenocytes were used at a
concentration of 8 × 105 cells/ well in complete medium
for 72 h in the presence of parasite antigens (10 μg/ml
FTAg or 20 μg B. malayi L3 extract; BmL3E), or
medium alone (negative control), in a total volume of
200 μl/well. Culture supernatants were stored at –20 °C
until analysis for cytokine (interferon(IFN)γ, interleukin
(IL)-4, IL-5 and IL-13) levels using a sandwich cytokine
ELISA (R&D Systems).
Statistical analysis
Where datasets were normally distributed (as determined
using the Shapiro-Wilk test), variance between groups
was determined using a one-way ANOVA and Dunnet’s
post-hoc test to compare test groups to control. Where
datasets were found to be non-Gaussian, variation across
groups was analysed using the Kruskall-Wallis test with
the Dunn’s post hoc-test to compare pairs of groups. Stat-
istical analysis was conducted using SPSS and Graphpad
Prism Software with a significance level of p < 0.05.
Results
Lipopeptide adjuvant Pam2 neutralises protection and
exacerbates disease in L. major vaccines
Mice vaccinated with ALM alone showed a partial but
non-significant reduction in lesion size, with no signifi-
cant difference in the AUC values between ALM-
vaccinated and the PBS-vaccinated control group
(Fig. 1A&B). When the gold standard CpG adjuvant was
included in the ALM vaccine, mice developed signifi-
cantly reduced lesions compared to either PBS- or
ALM-vaccinated mice, with reduced lesion sizes from 4-
9 weeks post infection and significantly reduced AUCs.
The addition of Pam3 appeared to neutralise the partial
reduction of ALM alone and showed a similar profile to
PBS control group. Notably, when Pam2 was used with
ALM, the lesion sizes were significantly increased when
compared to sham vaccinated (PBS) mice from 4 weeks
p.i., and the AUC values were also significantly increased
(Fig. 1A&B). Thus, when compared to the gold standard
TLR agonist adjuvant CpG, lipopeptide adjuvants have
an opposing effect on lesion development post-challenge
when used in a vaccine for cutaneous leishmaniasis.
Pam2 drives a predominantly Th2 type immune response
characterised by elevated IgG1 levels following ALM
vaccination
In order to determine whether there were differences in
the magnitude or polarization of adaptive immune re-
sponses post-challenge, we measured the ratio of
antigen-specific IgG1:IgG2c antibody levels as a marker
of the Th1/Th2 polarisation [31]. Antigen-specific IgG1
responses were significantly elevated in the ALM + Pam2
vaccinated mice (and not ALM vaccinated mice), when
compared to PBS (sham) vaccinated controls, suggesting
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that the Pam2 lipopeptide adjuvant results in elevated
Th2 antibody responses.
When Pam2 or Pam3 was included in an ALM vac-
cine, there was a significant shift towards a Th2 response
to L. major antigen when compared to PBS- vaccinated
mice (Fig. 2B), as demonstrated by elevated IgG1:IgG2c
levels in the plasma. In contrast, those vaccinated with
ALM +CpG had the lowest IgG1:IgG2c ratio compared
to all other groups (p < 0.005). Thus, both the lipopep-
tide adjuvants skewed the immune response towards a
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Fig. 1 Development of L. major disease in mice vaccinated with ALM and adjuvants. Groups of 7-8 mice were vaccinated twice with one of the
following formulations: PBS; ALM; ALM + CpG; ALM + Pam2; ALM + Pam3 and were subsequently challenged four weeks after the second dose
with L. major promastigotes in the right hind foot (RHF). a Lesion development was monitored by measuring the difference in thickness of the
infected and uninfected feet (RHF-LHF) in mm; mean values + SEM are shown (* p <0.05; p < 0.005 **; p < 0.0001). b The overall disease severity is
summarised by calculating the area under the curve (AUC) from weekly lesion size data sets (mean + SEM is shown). A single experiment was
performed, adequately powered to detect a difference of < 40 % between lesion sizes in different groups. For both datasets, normality
was observed and thus variance between groups was determined using a one way ANOVA, with Dunnet’s post hoc test to determine
differences between test groups and the PBS control (* p <0.05; p < 0.005 **; p < 0.0001)
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Fig. 2 Antigen specific IgG antibody responses to FTAg in vaccinated mice infected with L. major for 9 weeks. Groups of 7-8 mice were
vaccinated twice with one of the following formulations: PBS; ALM; ALM + CpG; ALM + Pam2; ALM + Pam3 and challenged four weeks later with
L. major. Plasma samples were collected after 9 weeks of infection with L. major. a Levels of IgG1 and IgG2c antibodies specific for L. major FTAg
were determined by ELISA, results are displayed as Absorbance (Abs) at 450-570 nm; bars represent the mean + SEM values for the average levels
of antibody (from duplicate samples for each individual) in each group. b The ratio of IgG1:IgG2c was estimated using the mean absorbance
values for each individual (from supplicate values); points represent the ratio of mean antibody levels (IgG1:IgG2c) for each individual. A single
experiment was performed, adequately powered to detect a difference of < 40 % between lesion sizes in different groups. Variation
between groups was determined by conducting a one-way ANOVA test with Dunnet’s post hoc test to compare test groups with
controls (p < 0.05 *; p < 0.005 **; p < 0.0001)
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Th2 type when compared to CpG adjuvant or when
mice were unexposed to antigen prior to infection, based
on parasite-specific antibody profiling. Levels of Th1 and
Th2 cytokines were measured after in vitro stimulation
of splenocytes with L .major antigen FTAg, but the re-
sults failed to demonstrate clear differences in adaptive
immune responses between groups (data not shown).
This is likely due to the late time point during infection
(week 9) at which the splenocytes were recovered, as at
this point all groups have a predominant Th1 response,
have begun to control the infection and reduce lesion
sizes.
Pam2 reduces parasite burden and drives a Th2 response
in a vaccine model of filariasis
Because of the exacerbation of disease and Th2-skewed
immune profile in the context of Leishmania vaccin-
ation, we subsequently tested the use of Pam2 as an ad-
juvant for vaccines that require Th2 responses for
protective immunity, by utilising a vaccine model of the
human lymphatic filaria, B. malayi. Four weeks prior to
challenge infection mice were vaccinated with either
PBS, a gold-standard whole heat-killed Brugia L3 larval
preparation (HKBmL3), a filarial antigen extract
(BmMfE), BmMfE + Alum, or BmMfE + Pam2. For
HKBmL3, mice received a boost two weeks prior to
challenge. Mice vaccinated with the filarial extract
BmMfE alone showed non-significant reduction in the
average parasite recovery in contrast with the gold-
standard HKBmL3 vaccine (Fig. 3A). However, when
mice were vaccinated with BmMfE + Alum, a significant
mean 43 % reduction in parasite recovery compared to
challenge controls was observed (Fig. 3B). When the
Pam2 adjuvant was used, a similar, mean (41 %) signifi-
cant reduction in parasite recovery was observed. Thus,
Pam2 adjuvancy was able to reduce parasite burdens to
levels comparable to the gold standard Th2-driving
Alum.
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Fig. 3 The use of Pam2 adjuvant in a vaccine model for filariasis. Groups of 5 BALB/c mice were vaccinated with either a PBS control, HKBmL3
twice, 14 days apart or formulations containing BmMfE with or without the test adjuvants Pam2 or Alum once, s.c. to the nape of the neck.
Fourteen days after final vaccination, mice were challenged by infection of 50 B. malayi L3 larvae by intraperitoneal injection. a & b Parasite
recoveries 6 days after infection are presented, data is pooled from 2-3 individual experiments; median +/- interquartile is shown. c At the time
of challenge recovery, blood and plasma were collected and plasma samples were used to measure the amount of circulating IgG antibody
isotypes specific for the vaccine antigen BmMfE; levels of relative IgG1 and IgG2a are shown. d The ratio of IgG1:IgG2a levels is also shown.
Data presented is pooled from 2 experiments; median averages are shown. Variation between groups was determined by conducting a
Kruskall-wallis test with Dunn’s post hoc test to compare test groups with PBS controls (p < 0.05 *; p < 0.005 **; p < 0.001***)
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The greatest IgG1 responses were recorded in individ-
uals vaccinated with BmMfE + Pam2 (0.83 +/- 0.26),
followed by BmMfE + Alum (0.413 +/- 0.129) and
BmMfE (0.071 +/- 0.019), and both groups vaccinated
with adjuvants produced significantly higher levels of
IgG1 compared to those vaccinated with PBS alone
(Fig. 3B). Thus Pam2 is able to induce a more pro-
nounced increase in the antigen specific IgG1 response
when compared to Alum.
The levels of antigen specific IgG2a antibody were also
elevated in the BmMfE + Pam2 group and BmMfE +
Alum group compared to the sham vaccinated mice, in-
dicating that Pam2 is able to drive a mixed Th1/Th2 re-
sponse (Fig. 3B). This was further reflected in the ratios
of IgG1:IgG2a levels found in the plasma of the vacci-
nated mice, with the highest elevated levels recorded in
the group which received the Alum adjuvant, but with
all of the vaccine groups showing elevated IgG1:IgG2a
levels compared to PBS controls. Thus, Pam2 is a strong
driver of both IgG1 and IgG2a responses, and is com-
parable to Alum in its ability to drive strong antibody
responses. When splenocytes were isolated from chal-
lenged mice and re-stimulated with infectious-stage
parasite antigen (B. malayi L3 extract; BmL3E) cytokine
production indicated a significant elevation of Th2 cyto-
kines; IL-4, IL-13 and IL-5 (but not the Th1 cytokine
IFNγ) in mice vaccinated with BmMfE + Pam2. In con-
trast, vaccination with Alum had no effect on cytokine
recall responses at the time-point assayed (Fig. 4).
Discussion
Lipopeptides are TLR2-activating molecules that have
potential use as new adjuvants for vaccines [24, 32, 33].
They can induce both Th1 and Th2 immunity and are
particularly effective at promoting antibody and cyto-
toxic T-lymphocyte (CTL) effector and memory re-
sponses through enhanced priming of dendritic cells
[34]. Here we explored their use in two different models
of parasitic vaccination, in which protective immunity is
polarised towards either Th1 (L. major) or Th2 (B.
malayi) immunity.
The rationale for evaluating lipopeptides as adjuvants
for Leishmania vaccines is based on our previous work,
which demonstrates a protective role for TLR2 in infec-
tions with both L. major and L. mexicana (Halliday et al.
manuscript in preparation). We hypothesised that
Fig. 4 L3 specific splenocyte cytokine responses of vaccinated mice and controls in the B. malayi vaccine model. Splenocytes were recovered
from vaccinated mice challenged with B. malayi L3 larvae, 6 days after challenge. Levels of cytokine (IL-4, IL-13, IFNγ and IL-5) produced by
unstimulated cells were subtracted from those produced in the presence of BmL3E. Those sham vaccinated with PBS are shown (black circles),
as well as those vaccinated with BmMfE, BmMfE + Pam2, and BmMfE + Alum (grey triangles, light grey inverted triangles, and dark grey diamonds
respectively). Individual points represent the mean average levels of cytokine calculated from triplicate splenocyte cultures per mouse, and
horizontal bars represent median averages for each group. Data presented is from one individual experiment but is representative of 2. Variation
between groups was determined by conducting a Kruskall-wallis test with Dunn’s post hoc test to compare test groups with PBS controls (p < 0.05 *)
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TLR2-activating adjuvants would enhance the efficacy of
whole cell Leishmania vaccines. However, we observed
the opposite effect with lipopeptide adjuvants, which
neutralised vaccine efficacy and, in the case of Pam2, ex-
acerbated the severity of challenge infection. Whilst this
is in contrast to a previous study that showed a
lipopeptide-containing recombinant vaccine gave en-
hanced protection against L. major challenge and drove
a strong Th1 immune response [35], trace endotoxin
contaminants and other PAMPs derived from the ex-
pression system may explain difference in outcome. In
our study, pure, synthetic lipopeptides resulted in the
promotion of Th2 immune responses over the Th1 re-
sponse, in contrast to the Th1 driving CpG adjuvant,
which provided increased protection to L. major. This
was manifest in the ratio of IgG1:IgG2c levels in the ALM
+ Pam2 and to a lesser extent ALM+ Pam3 vaccinated
mice, which were skewed in favour of IgG1. Several stud-
ies have linked Leishmania-specific IgG [36, 37], and in
particular IgG1 antibody isotypes [38] to susceptibility to
infection with L. major or other Leishmania spp. During
infection, amastigotes are able to infect new macrophages
via IgG antibody receptors (FcγRs), resulting in produc-
tion of IL-10 at the site of infection and allowing further
parasite replication [39]. The elevated IgG1 levels in the
Pam2 vaccinated mice therefore may have a direct role for
the elevated disease severity observed in these mice. Alter-
natively, lipopeptide-driven expansion of Foxp3+ CD25+
CD4+ regulatory T cells may also compromise protective
Th1 immunity [40]. The finding that Pam2 has a higher
potency in the L. major model when compared to Pam3
(in terms of enhancing disease severity and driving
antigen-specific antibody responses), is consistent with the
findings of others [41], and may relate to the higher solu-
bility characteristics of Pam2.
Conversely to the deleterious effects in the L. major
vaccine model, when Pam2 was included in the B.
malayi vaccine, it promoted protective immunity with
similar efficacy to Alum adjuvants. In the B. malayi vac-
cine, elevated IgG1 levels were also observed in chal-
lenged mice when Pam2 was included in the vaccine. In
addition, an elevated production of IL-4, IL-13 and IL-5
was observed after the ex vivo stimulation of spleno-
cytes, again showing an elevated Th2 response with
Pam2. An elevated level of antigen-specific IgG2a was
also detected in mice vaccinated with the B. malayi +
Pam2 vaccine, which was not observed in the L. major
model (for IgG2c). This may reflect a differential re-
sponse to the Pam2 adjuvant between the strains of mice
used (C57BL/6 vs BALB/c), to the difference in antigen
and/or challenge pathogen used in the model, or indeed
to the chronicity of challenge infection (9 weeks or 6-9
days respectively). Importantly, whilst both Alum and
Pam2 elevated both antigen specific IgG1 and IgG2a
levels in the B. malayi model, the ratio of IgG1:IgG2a in
B. malayi + Pam2 vaccinated mice was lower compared
to Alum, indicating that Alum is a more selective driver
of Th2 rather than Th1 responses (reported before in
mice [42]). Alum adjuvants are able to stimulate en-
hanced innate immune responses at the site of exposure,
in a mechanism independent of TLR signalling (via
MyD88 and/or Trif ) [43]. Thus, while Alum and Pam2
both act to enhance innate and adaptive immune re-
sponses, the mechanism of action by which they do this
is strikingly different, as Pam2 drives immune responses
via engaging with TLR2/6, and via MyD88 signalling
[44]. Mechanisms which have been attributed to Alum’s
ability to potentiate immune responses include activa-
tion of the NOD-like receptor family, pyrin-domain-
containing 3 (NLRP3) inflammasome [45], and induction
of cell death followed by subsequent release of endogen-
ous danger signals [46]. However, the importance of each
of these in the ability of Alum to drive adaptive immune
responses is still a subject of debate, as some groups have
yet to find evidence of the involvement of the NLRP3
inflammasome upon exposure to Alum [46–48].
Humoral responses have important roles in parasite
clearance in lymphatic filariasis [49, 50]. B cell deficient
mice were unable to reduce parasite burden after pre-
exposure to irradiated L3 vaccine [50]. A recent study by
Sharmila et al. explored the use of a recombinant lipi-
dated antigen of filarial parasites, abundant larval tran-
script (ALT), in a rodent model of B. malayi infection
[51]. This study corroborates our findings as they also
demonstrate that the addition of a free diacylated lipo-
peptide adjuvant can enhance protection, and drive in-
creased antibody and cytokine responses when included
in a vaccine with native protein antigen [51]. It is inter-
esting that studies exploring the use of vaccines contain-
ing recombinant antigens engineered to harbour
intrinsically-linked lipid adjuvants report that such
formulations are able to drive strong immune response
of a Th1-type, in models of both L. major and B. malayi
[35, 51]. Thus, the influence of a lipopeptide adjuvant on
the resultant immune responses may differ dramatically
depending on the way in which it is presented; with free
lipopeptide adjuvants favouring an antibody and mixed
Th1/Th2 response, whilst intrinsically linked antigen
and lipopeptide formulations favour a Th1 response.
Further, free lipopeptides formulated so that they can
electrostatically attach to antigens appear to favour en-
hanced cellular immunity [34].
Previous studies exploring the use of lipopeptide adju-
vants have reported various types of immune responses,
ranging from elevated IL-10 and/or T regulatory cell re-
sponses [40, 52, 53], to enhanced Th1 responses [54–56].
Pandey et al. recently demonstrated that while Pam3 and
peptidoglycan (PGN) can enhance infection of L. major in
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macrophages in vitro, a diacylated lipopeptide BPPcysM-
PEG can reduce infection [55]. Furthermore, BPPcysM-
PEG was able to reduce L. major infection in both
prophylactic and therapeutic settings in a BALB/c model
[55], which is in contrast to the enhanced diseased caused
by Pam2 in our experiments. It is evident that the conflict-
ing findings in the literature on the immune response
elicited by lipopeptide adjuvants, suggests that the subse-
quent immune response is not an intrinsic property of the
lipopeptides but is influenced by the lipopeptide-vaccine
combination. This contrasts with other TLR ligand adju-
vants, which consistently drive strong Th1 immunity [1].
Further research to define under which circumstances
lipopeptide adjuvants promote polarised or mixed Th1/
Th2 immunity are required to support rational vaccine de-
sign [57, 58].
Conclusions
In summary, this study indicates that the use of Pam2 as
an adjuvant is able to drive improved efficacy in a hel-
minth vaccine model where Th2 immunity is required
for protective immunity, but is detrimental in vaccines
requiring Th1 immunity.
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